Subgroup analysis to explore potential signs of differential efficacy in terms of OS, PFS, and ORR by most relevant clinical features, including age, sex, performance status, tumor differentiation, Ki-67 range, plasma levels of tumor markers, tumor location, MSI status, PDL1 expression, were preplanned although the study was not powered for formal comparisons. This evidence concerns the gene MKI67 and neoplasm.